<!DOCTYPE html>
<html lang="it">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>O2-O3-AHT for Fibromyalgia | Consensus Manual</title>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jspdf/2.5.1/jspdf.umd.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/html2canvas/1.4.1/html2canvas.min.js"></script>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        :root {
            --primary: #2c5f7c;
            --secondary: #4a9eba;
            --accent: #e74c3c;
            --success: #27ae60;
            --warning: #f39c12;
            --text-dark: #2c3e50;
            --text-light: #ecf0f1;
            --bg-light: #f8f9fa;
            --bg-white: #ffffff;
        }

        /* Dark Mode Variables */
        [data-theme="dark"] {
            --text-dark: #ecf0f1;
            --text-light: #2c3e50;
            --bg-light: #1a1a1a;
            --bg-white: #2d2d2d;
            --primary: #4a9eba;
            --secondary: #2c5f7c;
        }

        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.6;
            color: var(--text-dark);
            overflow-x: hidden;
            background: var(--bg-white);
            transition: background-color 0.3s ease, color 0.3s ease;
        }

        /* Print Styles */
        @media print {
            nav, .mobile-menu, .cta-buttons, #theme-toggle, #lang-toggle, 
            #search-container, .comments-section, footer .footer-links {
                display: none !important;
            }
            
            body {
                background: white;
                color: black;
            }
            
            section {
                page-break-inside: avoid;
                padding: 1rem !important;
            }
            
            .card, .accordion-item {
                page-break-inside: avoid;
            }
            
            h1, h2, h3 {
                page-break-after: avoid;
            }
        }

        /* Navigation */
        nav {
            position: fixed;
            top: 0;
            width: 100%;
            background: linear-gradient(135deg, var(--primary), var(--secondary));
            padding: 1rem 0;
            box-shadow: 0 2px 10px rgba(0,0,0,0.1);
            z-index: 1000;
        }

        nav .container {
            max-width: 1200px;
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: center;
            padding: 0 2rem;
        }

        nav .logo {
            color: var(--text-light);
            font-size: 1.5rem;
            font-weight: bold;
            text-decoration: none;
        }

        nav ul {
            list-style: none;
            display: flex;
            gap: 2rem;
        }

        nav ul li a {
            color: var(--text-light);
            text-decoration: none;
            transition: color 0.3s;
            font-weight: 500;
        }

        nav ul li a:hover {
            color: var(--warning);
        }

        .mobile-menu {
            display: none;
            color: var(--text-light);
            font-size: 1.5rem;
            cursor: pointer;
        }

        /* Theme and Language Toggle */
        .nav-controls {
            display: flex;
            gap: 1rem;
            align-items: center;
        }

        .toggle-btn {
            background: rgba(255,255,255,0.2);
            border: 2px solid white;
            color: white;
            padding: 0.5rem 1rem;
            border-radius: 20px;
            cursor: pointer;
            font-size: 0.9rem;
            transition: all 0.3s;
        }

        .toggle-btn:hover {
            background: white;
            color: var(--primary);
        }

        /* Search Bar */
        #search-container {
            max-width: 600px;
            margin: 2rem auto;
            padding: 0 2rem;
        }

        #search-input {
            width: 100%;
            padding: 1rem;
            border: 2px solid var(--primary);
            border-radius: 50px;
            font-size: 1rem;
            background: var(--bg-white);
            color: var(--text-dark);
        }

        #search-results {
            margin-top: 1rem;
            background: var(--bg-white);
            border-radius: 10px;
            padding: 1rem;
            display: none;
        }

        .search-result-item {
            padding: 0.5rem;
            margin: 0.5rem 0;
            border-left: 3px solid var(--accent);
            background: var(--bg-light);
            cursor: pointer;
        }

        .search-result-item:hover {
            background: var(--primary);
            color: white;
        }

        /* Hero Section */
        .hero {
            margin-top: 70px;
            background: linear-gradient(135deg, var(--primary) 0%, var(--secondary) 100%);
            color: var(--text-light);
            padding: 6rem 2rem;
            text-align: center;
        }

        .hero h1 {
            font-size: 3rem;
            margin-bottom: 1rem;
            animation: fadeInDown 1s;
        }

        .hero p {
            font-size: 1.3rem;
            max-width: 800px;
            margin: 0 auto 2rem;
            opacity: 0.9;
        }

        .hero .authors {
            font-size: 1.1rem;
            margin-top: 1rem;
            opacity: 0.8;
        }

        .cta-buttons {
            display: flex;
            gap: 1rem;
            justify-content: center;
            margin-top: 2rem;
            flex-wrap: wrap;
        }

        .btn {
            padding: 1rem 2rem;
            border: none;
            border-radius: 50px;
            font-size: 1rem;
            cursor: pointer;
            transition: all 0.3s;
            text-decoration: none;
            display: inline-block;
        }

        .btn-primary {
            background: var(--accent);
            color: white;
        }

        .btn-primary:hover {
            background: #c0392b;
            transform: translateY(-3px);
            box-shadow: 0 5px 15px rgba(231, 76, 60, 0.3);
        }

        .btn-secondary {
            background: transparent;
            color: white;
            border: 2px solid white;
        }

        .btn-secondary:hover {
            background: white;
            color: var(--primary);
        }

        /* Container */
        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 0 2rem;
        }

        /* Sections */
        section {
            padding: 5rem 2rem;
        }

        section:nth-child(even) {
            background: var(--bg-light);
        }

        .section-title {
            font-size: 2.5rem;
            color: var(--primary);
            margin-bottom: 1rem;
            text-align: center;
        }

        .section-subtitle {
            font-size: 1.2rem;
            color: #7f8c8d;
            text-align: center;
            margin-bottom: 3rem;
            max-width: 700px;
            margin-left: auto;
            margin-right: auto;
        }

        /* Cards */
        .cards {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 2rem;
            margin-top: 3rem;
        }

        .card {
            background: var(--bg-white);
            padding: 2rem;
            border-radius: 15px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
            transition: all 0.3s;
            cursor: pointer;
        }

        .card:hover {
            transform: translateY(-10px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.15);
        }

        .card-icon {
            font-size: 3rem;
            margin-bottom: 1rem;
        }

        .card h3 {
            color: var(--primary);
            margin-bottom: 1rem;
            font-size: 1.5rem;
        }

        .card p {
            color: #555;
            line-height: 1.8;
        }

        /* Timeline */
        .timeline {
            position: relative;
            max-width: 900px;
            margin: 3rem auto;
        }

        .timeline::before {
            content: '';
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            width: 4px;
            height: 100%;
            background: var(--secondary);
        }

        .timeline-item {
            margin-bottom: 3rem;
            position: relative;
        }

        .timeline-item:nth-child(odd) {
            padding-right: 50%;
            text-align: right;
        }

        .timeline-item:nth-child(even) {
            padding-left: 50%;
            text-align: left;
        }

        .timeline-content {
            background: var(--bg-white);
            padding: 2rem;
            border-radius: 10px;
            box-shadow: 0 3px 15px rgba(0,0,0,0.1);
            position: relative;
        }

        .timeline-item::after {
            content: '';
            position: absolute;
            top: 20px;
            width: 20px;
            height: 20px;
            background: var(--accent);
            border: 4px solid var(--bg-white);
            border-radius: 50%;
            left: 50%;
            transform: translateX(-50%);
            z-index: 1;
        }

        .timeline-content h3 {
            color: var(--primary);
            margin-bottom: 0.5rem;
        }

        .timeline-content .phase {
            display: inline-block;
            background: var(--accent);
            color: white;
            padding: 0.3rem 1rem;
            border-radius: 20px;
            font-size: 0.9rem;
            margin-bottom: 1rem;
        }

        /* Stats */
        .stats {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 2rem;
            text-align: center;
            margin: 3rem 0;
        }

        .stat-box {
            background: var(--bg-white);
            padding: 2rem;
            border-radius: 15px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }

        .stat-number {
            font-size: 3rem;
            font-weight: bold;
            color: var(--accent);
            display: block;
        }

        .stat-label {
            color: #7f8c8d;
            font-size: 1rem;
            margin-top: 0.5rem;
        }

        /* Accordion */
        .accordion {
            max-width: 900px;
            margin: 3rem auto;
        }

        .accordion-item {
            background: var(--bg-white);
            margin-bottom: 1rem;
            border-radius: 10px;
            overflow: hidden;
            box-shadow: 0 3px 10px rgba(0,0,0,0.1);
        }

        .accordion-header {
            padding: 1.5rem;
            cursor: pointer;
            display: flex;
            justify-content: space-between;
            align-items: center;
            background: var(--primary);
            color: white;
            transition: background 0.3s;
        }

        .accordion-header:hover {
            background: var(--secondary);
        }

        .accordion-header h3 {
            margin: 0;
            font-size: 1.2rem;
        }

        .accordion-icon {
            font-size: 1.5rem;
            transition: transform 0.3s;
        }

        .accordion-item.active .accordion-icon {
            transform: rotate(180deg);
        }

        .accordion-content {
            max-height: 0;
            overflow: hidden;
            transition: max-height 0.3s ease;
            padding: 0 1.5rem;
        }

        .accordion-item.active .accordion-content {
            max-height: 1000px;
            padding: 1.5rem;
        }

        /* Protocol Visual */
        .protocol-visual {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 3rem;
            border-radius: 20px;
            margin: 3rem 0;
            text-align: center;
        }

        .protocol-steps {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(150px, 1fr));
            gap: 2rem;
            margin-top: 2rem;
        }

        .protocol-step {
            text-align: center;
        }

        .protocol-step-number {
            width: 60px;
            height: 60px;
            background: white;
            color: #667eea;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.5rem;
            font-weight: bold;
            margin: 0 auto 1rem;
        }

        /* Safety Alert */
        .safety-alert {
            background: linear-gradient(135deg, #ff6b6b, #ee5a6f);
            color: white;
            padding: 2rem;
            border-radius: 15px;
            margin: 3rem 0;
            border-left: 5px solid #c0392b;
        }

        .safety-alert h3 {
            display: flex;
            align-items: center;
            gap: 1rem;
            margin-bottom: 1rem;
        }

        .safety-alert-icon {
            font-size: 2rem;
        }

        /* Quiz Section */
        .quiz-container {
            background: var(--bg-white);
            padding: 2rem;
            border-radius: 15px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
            margin: 2rem 0;
        }

        .quiz-question {
            margin-bottom: 2rem;
        }

        .quiz-options {
            display: flex;
            flex-direction: column;
            gap: 1rem;
            margin-top: 1rem;
        }

        .quiz-option {
            padding: 1rem;
            background: var(--bg-light);
            border: 2px solid transparent;
            border-radius: 10px;
            cursor: pointer;
            transition: all 0.3s;
        }

        .quiz-option:hover {
            border-color: var(--primary);
        }

        .quiz-option.correct {
            background: #d4edda;
            border-color: var(--success);
        }

        .quiz-option.incorrect {
            background: #f8d7da;
            border-color: var(--accent);
        }

        /* Video Section */
        .video-container {
            max-width: 800px;
            margin: 2rem auto;
            border-radius: 15px;
            overflow: hidden;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }

        .video-container iframe {
            width: 100%;
            height: 450px;
            border: none;
        }

        /* Comments Section */
        .comments-section {
            max-width: 900px;
            margin: 3rem auto;
            background: var(--bg-white);
            padding: 2rem;
            border-radius: 15px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }

        .comment-form {
            margin-bottom: 2rem;
        }

        .comment-form textarea {
            width: 100%;
            padding: 1rem;
            border: 2px solid var(--primary);
            border-radius: 10px;
            font-family: inherit;
            font-size: 1rem;
            resize: vertical;
            min-height: 100px;
            background: var(--bg-white);
            color: var(--text-dark);
        }

        .comment-form input {
            width: 100%;
            padding: 0.8rem;
            margin-top: 1rem;
            border: 2px solid var(--primary);
            border-radius: 10px;
            font-family: inherit;
            background: var(--bg-white);
            color: var(--text-dark);
        }

        .comment-item {
            background: var(--bg-light);
            padding: 1.5rem;
            border-radius: 10px;
            margin-bottom: 1rem;
        }

        .comment-author {
            font-weight: bold;
            color: var(--primary);
        }

        .comment-date {
            font-size: 0.9rem;
            color: #7f8c8d;
            margin-left: 1rem;
        }

        /* Flowchart */
        .flowchart-container {
            background: var(--bg-white);
            padding: 3rem 2rem;
            border-radius: 15px;
            margin: 3rem 0;
            overflow-x: auto;
        }

        .flowchart {
            display: flex;
            align-items: center;
            justify-content: center;
            gap: 1rem;
            flex-wrap: wrap;
            min-height: 300px;
        }

        .flow-step {
            background: var(--success);
            color: white;
            padding: 1.5rem 2rem;
            border-radius: 15px;
            min-width: 150px;
            text-align: center;
            box-shadow: 0 3px 10px rgba(0,0,0,0.2);
            animation: flowBlink 3s infinite;
            opacity: 0.3;
        }

        .flow-step.active {
            opacity: 1;
            transform: scale(1.1);
        }

        .flow-arrow {
            font-size: 2rem;
            color: var(--primary);
        }

        @keyframes flowBlink {
            0%, 100% { opacity: 0.3; }
            50% { opacity: 1; }
        }

        /* Glossary */
        .glossary {
            max-width: 900px;
            margin: 3rem auto;
        }

        .glossary-item {
            background: var(--bg-white);
            padding: 1.5rem;
            margin-bottom: 1rem;
            border-radius: 10px;
            box-shadow: 0 3px 10px rgba(0,0,0,0.1);
        }

        .glossary-term {
            font-size: 1.2rem;
            font-weight: bold;
            color: var(--primary);
            margin-bottom: 0.5rem;
        }

        /* Footer */
        footer {
            background: var(--text-dark);
            color: var(--text-light);
            padding: 3rem 2rem;
            text-align: center;
        }

        footer .footer-content {
            max-width: 1200px;
            margin: 0 auto;
        }

        footer h3 {
            margin-bottom: 1rem;
        }

        footer .footer-links {
            display: flex;
            justify-content: center;
            gap: 2rem;
            margin: 2rem 0;
            flex-wrap: wrap;
        }

        footer a {
            color: var(--secondary);
            text-decoration: none;
            transition: color 0.3s;
        }

        footer a:hover {
            color: var(--warning);
        }

        .footer-credits {
            margin-top: 2rem;
            padding-top: 2rem;
            border-top: 1px solid rgba(255,255,255,0.1);
            font-size: 0.9rem;
        }

        /* Animations */
        @keyframes fadeInDown {
            from {
                opacity: 0;
                transform: translateY(-30px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }

        @keyframes fadeInUp {
            from {
                opacity: 0;
                transform: translateY(30px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }

        .fade-in {
            animation: fadeInUp 1s;
        }

        /* Scroll Progress Bar */
        .progress-bar {
            position: fixed;
            top: 70px;
            left: 0;
            height: 4px;
            background: var(--accent);
            width: 0%;
            z-index: 999;
            transition: width 0.1s;
        }

        /* Responsive */
        @media (max-width: 768px) {
            nav ul {
                display: none;
            }

            .mobile-menu {
                display: block;
            }

            nav ul.active {
                display: flex;
                flex-direction: column;
                position: absolute;
                top: 100%;
                left: 0;
                width: 100%;
                background: var(--primary);
                padding: 1rem;
                gap: 1rem;
            }

            .hero h1 {
                font-size: 2rem;
            }

            .hero p {
                font-size: 1rem;
            }

            .timeline::before {
                left: 30px;
            }

            .timeline-item:nth-child(odd),
            .timeline-item:nth-child(even) {
                padding-left: 80px;
                padding-right: 0;
                text-align: left;
            }

            .timeline-item::after {
                left: 30px;
            }

            .cta-buttons {
                flex-direction: column;
            }

            .nav-controls {
                flex-direction: column;
                gap: 0.5rem;
            }
        }

        /* Table styles */
        .responsive-table {
            overflow-x: auto;
            margin: 2rem 0;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            background: var(--bg-white);
            box-shadow: 0 3px 10px rgba(0,0,0,0.1);
            border-radius: 10px;
            overflow: hidden;
        }

        th {
            background: var(--primary);
            color: white;
            padding: 1rem;
            text-align: left;
        }

        td {
            padding: 1rem;
            border-bottom: 1px solid #ecf0f1;
        }

        tr:hover {
            background: var(--bg-light);
        }

        /* Biomarker visualization */
        .biomarker-viz {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 2rem;
            margin: 3rem 0;
        }

        .biomarker-card {
            background: var(--bg-white);
            padding: 1.5rem;
            border-radius: 15px;
            box-shadow: 0 3px 15px rgba(0,0,0,0.1);
        }

        .biomarker-card h4 {
            color: var(--primary);
            margin-bottom: 1rem;
        }

        .progress-meter {
            height: 10px;
            background: #ecf0f1;
            border-radius: 10px;
            overflow: hidden;
            margin: 1rem 0;
        }

        .progress-meter-fill {
            height: 100%;
            background: linear-gradient(90deg, var(--accent), var(--success));
            transition: width 1s ease;
        }

        /* Language specific content */
        [lang="it"] .lang-en { display: none; }
        [lang="en"] .lang-it { display: none; }
    </style>
</head>
<body>
    <!-- Progress Bar -->
    <div class="progress-bar" id="progressBar"></div>

    <!-- Navigation -->
    <nav>
        <div class="container">
            <a href="#" class="logo">ü´Å O‚ÇÇ-O‚ÇÉ-AHT Manual</a>
            <ul id="navMenu">
                <li><a href="#intro" class="lang-it">Introduzione</a><a href="#intro" class="lang-en">Introduction</a></li>
                <li><a href="#pathophysiology" class="lang-it">Fisiopatologia</a><a href="#pathophysiology" class="lang-en">Pathophysiology</a></li>
                <li><a href="#mechanism" class="lang-it">Meccanismo</a><a href="#mechanism" class="lang-en">Mechanism</a></li>
                <li><a href="#protocol" class="lang-it">Protocollo</a><a href="#protocol" class="lang-en">Protocol</a></li>
                <li><a href="#safety" class="lang-it">Sicurezza</a><a href="#safety" class="lang-en">Safety</a></li>
                <li><a href="#resources" class="lang-it">Risorse</a><a href="#resources" class="lang-en">Resources</a></li>
            </ul>
            <div class="nav-controls">
                <button id="theme-toggle" class="toggle-btn">üåì <span class="lang-it">Tema</span><span class="lang-en">Theme</span></button>
                <button id="lang-toggle" class="toggle-btn">üåê EN/IT</button>
            </div>
            <div class="mobile-menu" id="mobileMenu">‚ò∞</div>
        </div>
    </nav>

    <!-- Hero Section -->
    <section class="hero">
        <div class="container">
            <h1 class="lang-it">Ossigeno-Ozono Autoemotrasfusione per la Fibromialgia</h1>
            <h1 class="lang-en">Oxygen-Ozone Autohemotherapy for Fibromyalgia</h1>
            <p class="lang-it">Un manuale completo sul meccanismo, protocollo e terapia guidata da biomarcatori</p>
            <p class="lang-en">A Comprehensive Consensus Manual on Mechanism, Protocol, and Biomarker-Guided Therapy</p>
            <p class="authors"><span class="lang-it">A cura di</span><span class="lang-en">Edited by</span> Roberto Casale, MD & Piercarlo Sarzi-Puttini, MD</p>
            <div class="cta-buttons">
                <a href="#protocol" class="btn btn-primary"><span class="lang-it">Vedi Protocollo</span><span class="lang-en">View Protocol</span></a>
                <button onclick="downloadPDF()" class="btn btn-secondary">üìÑ <span class="lang-it">Scarica PDF</span><span class="lang-en">Download PDF</span></button>
                <a href="#" onclick="downloadOriginalManual()" class="btn btn-secondary">üìö <span class="lang-it">Manuale Originale</span><span class="lang-en">Original Manual</span></a>
            </div>
        </div>
    </section>

    <!-- Search Section -->
    <div id="search-container">
        <input type="text" id="search-input" placeholder="üîç Cerca nel manuale... / Search the manual...">
        <div id="search-results"></div>
    </div>

    <!-- Introduction -->
    <section id="intro">
        <div class="container">
            <h2 class="section-title"><span class="lang-it">Comprendere la Fibromialgia</span><span class="lang-en">Understanding Fibromyalgia</span></h2>
            <p class="section-subtitle"><span class="lang-it">Un disturbo complesso del dolore cronico che colpisce il 2-4% della popolazione globale</span><span class="lang-en">A complex chronic pain disorder affecting 2-4% of the global population</span></p>
            
            <div class="stats">
                <div class="stat-box">
                    <span class="stat-number">2-4%</span>
                    <span class="stat-label"><span class="lang-it">Prevalenza Globale</span><span class="lang-en">Global Prevalence</span></span>
                </div>
                <div class="stat-box">
                    <span class="stat-number">7:1</span>
                    <span class="stat-label"><span class="lang-it">Rapporto Femmine:Maschi</span><span class="lang-en">Female:Male Ratio</span></span>
                </div>
                <div class="stat-box">
                    <span class="stat-number">50%</span>
                    <span class="stat-label"><span class="lang-it">Con Patologia Fibre Piccole</span><span class="lang-en">With Small Fiber Pathology</span></span>
                </div>
                <div class="stat-box">
                    <span class="stat-number">&lt;50%</span>
                    <span class="stat-label"><span class="lang-it">Risposta ai Farmaci Attuali</span><span class="lang-en">Response to Current Meds</span></span>
                </div>
            </div>

            <div class="cards">
                <div class="card">
                    <div class="card-icon">üéØ</div>
                    <h3><span class="lang-it">Evoluzione Diagnostica</span><span class="lang-en">Diagnostic Evolution</span></h3>
                    <p class="lang-it">Dai tender points ACR del 1990 ai criteri del 2016 incentrati sull'indice del dolore diffuso (WPI) e sulla scala di gravit√† dei sintomi (SSS), ora classificato sotto il dolore primario cronico ICD-11.</p>
                    <p class="lang-en">From 1990 ACR tender points to 2016 criteria focusing on widespread pain index (WPI) and symptom severity scale (SSS), now classified under ICD-11 chronic primary pain.</p>
                </div>
                <div class="card">
                    <div class="card-icon">üß¨</div>
                    <h3><span class="lang-it">Stress Ossidativo</span><span class="lang-en">Oxidative Stress</span></h3>
                    <p class="lang-it">Elevati MDA, AOPP e ridotta capacit√† antiossidante (TAC, GSH, SOD, GPx) indicano un profondo squilibrio redox cellulare come meccanismo fisiopatologico centrale.</p>
                    <p class="lang-en">Elevated MDA, AOPP, and reduced antioxidant capacity (TAC, GSH, SOD, GPx) indicate profound cellular redox imbalance as a core pathophysiological mechanism.</p>
                </div>
                <div class="card">
                    <div class="card-icon">‚ö°</div>
                    <h3><span class="lang-it">Disfunzione Mitocondriale</span><span class="lang-en">Mitochondrial Dysfunction</span></h3>
                    <p class="lang-it">Attivit√† ridotta del Complesso I, sintesi ATP ridotta e deficit energetici cellulari contribuiscono alla fatica e all'intolleranza all'esercizio caratteristiche della FM.</p>
                    <p class="lang-en">Impaired Complex I activity, reduced ATP synthesis, and cellular energy deficits contribute to fatigue and exercise intolerance characteristic of FM.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Pathophysiology -->
    <section id="pathophysiology">
        <div class="container">
            <h2 class="section-title"><span class="lang-it">Fisiopatologia e Patologia delle Piccole Fibre</span><span class="lang-en">Pathophysiology & Small Fiber Pathology</span></h2>
            <p class="section-subtitle"><span class="lang-it">Molteplici meccanismi interconnessi alla base dei sintomi della FM</span><span class="lang-en">Multiple interconnected mechanisms underlying FM symptoms</span></p>

            <div class="cards">
                <div class="card">
                    <div class="card-icon">üî¨</div>
                    <h3><span class="lang-it">Neuropatia delle Piccole Fibre</span><span class="lang-en">Small Fiber Neuropathy</span></h3>
                    <p class="lang-it">Il 40-50% dei pazienti con FM mostra una densit√† ridotta delle fibre nervose intraepidermiche (IENFD) alla biopsia cutanea, fornendo una patologia strutturale oggettiva.</p>
                    <p class="lang-en">40-50% of FM patients show reduced intraepidermal nerve fiber density (IENFD) on skin biopsy, providing objective structural pathology.</p>
                </div>
                <div class="card">
                    <div class="card-icon">üß†</div>
                    <h3><span class="lang-it">Sensibilizzazione Centrale</span><span class="lang-en">Central Sensitization</span></h3>
                    <p class="lang-it">Amplificazione dei segnali del dolore nel SNC, elaborazione aberrante del dolore e neuroinfiammazione con attivazione gliale.</p>
                    <p class="lang-en">Amplification of pain signals in the CNS, aberrant pain processing, and neuroinflammation with glial activation.</p>
                </div>
                <div class="card">
                    <div class="card-icon">üî•</div>
                    <h3><span class="lang-it">Neuroinfiammazione</span><span class="lang-en">Neuroinflammation</span></h3>
                    <p class="lang-it">Elevati IL-6, TNF-Œ±, IL-1Œ≤ e hsCRP creano un microambiente pro-infiammatorio che danneggia le fibre nervose.</p>
                    <p class="lang-en">Elevated IL-6, TNF-Œ±, IL-1Œ≤, and hsCRP creating pro-inflammatory microenvironment that damages nerve fibers.</p>
                </div>
            </div>

            <div class="responsive-table" style="margin-top: 3rem;">
                <table>
                    <thead>
                        <tr>
                            <th><span class="lang-it">Biomarcatore</span><span class="lang-en">Biomarker</span></th>
                            <th><span class="lang-it">Intervallo Normale</span><span class="lang-en">Normal Range</span></th>
                            <th><span class="lang-it">FM Tipico</span><span class="lang-en">FM Typical</span></th>
                            <th><span class="lang-it">Significato Clinico</span><span class="lang-en">Clinical Significance</span></th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>MDA</strong></td>
                            <td>&lt;2.0 Œºmol/L</td>
                            <td>2.5-4.5 Œºmol/L</td>
                            <td><span class="lang-it">Marcatore di perossidazione lipidica</span><span class="lang-en">Lipid peroxidation marker</span></td>
                        </tr>
                        <tr>
                            <td><strong>TAC</strong></td>
                            <td>1.3-1.8 mmol/L</td>
                            <td>0.8-1.2 mmol/L</td>
                            <td><span class="lang-it">Capacit√† antiossidante totale</span><span class="lang-en">Total antioxidant capacity</span></td>
                        </tr>
                        <tr>
                            <td><strong>hsCRP</strong></td>
                            <td>&lt;1 mg/L</td>
                            <td>3-8 mg/L</td>
                            <td><span class="lang-it">Infiammazione sistemica</span><span class="lang-en">Systemic inflammation</span></td>
                        </tr>
                        <tr>
                            <td><strong>GSH:GSSG</strong></td>
                            <td>&gt;10:1</td>
                            <td>5:1 to 8:1</td>
                            <td><span class="lang-it">Stato redox cellulare</span><span class="lang-en">Cellular redox status</span></td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>
    </section>

    <!-- Nrf2 Mechanism -->
    <section id="mechanism">
        <div class="container">
            <h2 class="section-title"><span class="lang-it">Via Nrf2 e Meccanismo Ormetico</span><span class="lang-en">Nrf2 Pathway & Hormetic Mechanism</span></h2>
            <p class="section-subtitle"><span class="lang-it">Come l'O‚ÇÇ-O‚ÇÉ-AHT innesca risposte adattative benefiche</span><span class="lang-en">How O‚ÇÇ-O‚ÇÉ-AHT triggers beneficial adaptive responses</span></p>

            <div class="protocol-visual">
                <h3><span class="lang-it">Principio Ormetico</span><span class="lang-en">Hormetic Principle</span></h3>
                <p><span class="lang-it">Lo stress ossidativo a basso dosaggio attiva Nrf2, innescando l'upregolazione di oltre 200 geni citoprotettivi</span><span class="lang-en">Low-dose oxidative stress activates Nrf2, triggering upregulation of 200+ cytoprotective genes</span></p>
                <div class="protocol-steps">
                    <div class="protocol-step">
                        <div class="protocol-step-number">1</div>
                        <h4><span class="lang-it">Contatto Ozono</span><span class="lang-en">Ozone Contact</span></h4>
                        <p><span class="lang-it">Genera LOPs (4-HNE, MDA)</span><span class="lang-en">Generates LOPs (4-HNE, MDA)</span></p>
                    </div>
                    <div class="protocol-step">
                        <div class="protocol-step-number">2</div>
                        <h4><span class="lang-it">Ossidazione Keap1</span><span class="lang-en">Keap1 Oxidation</span></h4>
                        <p><span class="lang-it">Rilascia Nrf2</span><span class="lang-en">Releases Nrf2</span></p>
                    </div>
                    <div class="protocol-step">
                        <div class="protocol-step-number">3</div>
                        <h4><span class="lang-it">Traslocazione Nucleare</span><span class="lang-en">Nuclear Translocation</span></h4>
                        <p><span class="lang-it">Nrf2 entra nel nucleo</span><span class="lang-en">Nrf2 enters nucleus</span></p>
                    </div>
                    <div class="protocol-step">
                        <div class="protocol-step-number">4</div>
                        <h4><span class="lang-it">Legame ARE</span><span class="lang-en">ARE Binding</span></h4>
                        <p><span class="lang-it">Attiva trascrizione genica</span><span class="lang-en">Activates gene transcription</span></p>
                    </div>
                    <div class="protocol-step">
                        <div class="protocol-step-number">5</div>
                        <h4><span class="lang-it">Produzione Enzimi</span><span class="lang-en">Enzyme Production</span></h4>
                        <p>SOD, CAT, GPx, HO-1 ‚Üë</p>
                    </div>
                </div>
            </div>

            <h3 style="text-align: center; margin: 3rem 0 2rem; color: var(--primary);"><span class="lang-it">Dinamiche Temporali</span><span class="lang-en">Temporal Dynamics</span></h3>
            <div class="timeline">
                <div class="timeline-item">
                    <div class="timeline-content">
                        <span class="phase"><span class="lang-it">Fase Immediata</span><span class="lang-en">Immediate Phase</span></span>
                        <h3>0-30 <span class="lang-it">minuti</span><span class="lang-en">minutes</span></h3>
                        <p class="lang-it">I LOPs derivati dall'ozono (4-HNE) modificano covalentemente i residui di cisteina di Keap1, interrompendo l'interazione Keap1-Nrf2. L'attivazione MAPK fosforila Nrf2, facilitando la traslocazione nucleare.</p>
                        <p class="lang-en">Ozone-derived LOPs (4-HNE) covalently modify Keap1 cysteine residues, disrupting Keap1-Nrf2 interaction. MAPK activation phosphorylates Nrf2, facilitating nuclear translocation.</p>
                    </div>
                </div>
                <div class="timeline-item">
                    <div class="timeline-content">
                        <span class="phase"><span class="lang-it">Fase Acuta</span><span class="lang-en">Acute Phase</span></span>
                        <h3><span class="lang-it">Minuti a 6 ore</span><span class="lang-en">Minutes to 6 hours</span></h3>
                        <p class="lang-it">Nrf2 stabilizzato si accumula e si trasloca al nucleo, eterodimerizzando con le proteine Maf e legandosi agli ARE. Inizia l'attivazione trascrizionale della batteria genica Nrf2.</p>
                        <p class="lang-en">Stabilized Nrf2 accumulates and translocates to nucleus, heterodimerizing with Maf proteins and binding to AREs. Transcriptional activation of Nrf2 gene battery begins.</p>
                    </div>
                </div>
                <div class="timeline-item">
                    <div class="timeline-content">
                        <span class="phase"><span class="lang-it">Fase Adattativa</span><span class="lang-en">Adaptive Phase</span></span>
                        <h3>6-72 <span class="lang-it">ore</span><span class="lang-en">hours</span></h3>
                        <p class="lang-it">Espressione di picco degli enzimi antiossidanti (aumenti di 5-10 volte). Massima resistenza allo stress cellulare e capacit√† anti-infiammatoria. Ripristino dell'omeostasi redox.</p>
                        <p class="lang-en">Peak expression of antioxidant enzymes (5-10 fold increases). Maximum cellular stress resistance and anti-inflammatory capacity. Redox homeostasis restoration.</p>
                    </div>
                </div>
                <div class="timeline-item">
                    <div class="timeline-content">
                        <span class="phase"><span class="lang-it">Fase di Risoluzione</span><span class="lang-en">Resolution Phase</span></span>
                        <h3>3-14 <span class="lang-it">giorni</span><span class="lang-en">days</span></h3>
                        <p class="lang-it">Nrf2 ritorna al livello basale ma le proteine citoprotettive persistono a causa delle lunghe emivite. La resistenza allo stress aumentata viene mantenuta, fornendo la base per gli intervalli tra i trattamenti.</p>
                        <p class="lang-en">Nrf2 returns to baseline but cytoprotective proteins persist due to long half-lives. Enhanced stress resistance maintained, providing basis for inter-treatment intervals.</p>
                    </div>
                </div>
            </div>

            <div class="biomarker-viz">
                <div class="biomarker-card">
                    <h4><span class="lang-it">Riduzione MDA</span><span class="lang-en">MDA Reduction</span></h4>
                    <p><span class="lang-it">Diminuzione del 20-40%</span><span class="lang-en">20-40% decrease</span></p>
                    <div class="progress-meter">
                        <div class="progress-meter-fill" style="width: 35%"></div>
                    </div>
                    <small><span class="lang-it">Indica ridotta perossidazione lipidica</span><span class="lang-en">Indicates reduced lipid peroxidation</span></small>
                </div>
                <div class="biomarker-card">
                    <h4><span class="lang-it">Aumento TAC</span><span class="lang-en">TAC Increase</span></h4>
                    <p><span class="lang-it">Aumento del 20-40%</span><span class="lang-en">20-40% increase</span></p>
                    <div class="progress-meter">
                        <div class="progress-meter-fill" style="width: 30%"></div>
                    </div>
                    <small><span class="lang-it">Riserve antiossidanti potenziate</span><span class="lang-en">Enhanced antioxidant reserves</span></small>
                </div>
                <div class="biomarker-card">
                    <h4><span class="lang-it">Diminuzione hsCRP</span><span class="lang-en">hsCRP Decrease</span></h4>
                    <p><span class="lang-it">Riduzione del 30-50%</span><span class="lang-en">30-50% reduction</span></p>
                    <div class="progress-meter">
                        <div class="progress-meter-fill" style="width: 40%"></div>
                    </div>
                    <small><span class="lang-it">Ridotta infiammazione sistemica</span><span class="lang-en">Reduced systemic inflammation</span></small>
                </div>
                <div class="biomarker-card">
                    <h4><span class="lang-it">Riduzione Dolore</span><span class="lang-en">Pain Reduction</span></h4>
                    <p><span class="lang-it">Diminuzione del 30-40%</span><span class="lang-en">30-40% decrease</span></p>
                    <div class="progress-meter">
                        <div class="progress-meter-fill" style="width: 35%"></div>
                    </div>
                    <small><span class="lang-it">Miglioramento punteggio VAS</span><span class="lang-en">VAS score improvement</span></small>
                </div>
            </div>
        </div>
    </section>

    <!-- Interactive Flowchart -->
    <section id="flowchart">
        <div class="container">
            <h2 class="section-title"><span class="lang-it">Flowchart Interattivo del Trattamento</span><span class="lang-en">Interactive Treatment Flowchart</span></h2>
            <div class="flowchart-container">
                <div class="flowchart" id="interactiveFlowchart">
                    <div class="flow-step" data-step="1"><span class="lang-it">Valutazione Paziente</span><span class="lang-en">Patient Assessment</span></div>
                    <div class="flow-arrow">‚Üí</div>
                    <div class="flow-step" data-step="2"><span class="lang-it">Screening G6PD</span><span class="lang-en">G6PD Screening</span></div>
                    <div class="flow-arrow">‚Üí</div>
                    <div class="flow-step" data-step="3"><span class="lang-it">Biomarcatori Basali</span><span class="lang-en">Baseline Biomarkers</span></div>
                    <div class="flow-arrow">‚Üí</div>
                    <div class="flow-step" data-step="4"><span class="lang-it">Fase Intensiva</span><span class="lang-en">Intensive Phase</span></div>
                    <div class="flow-arrow">‚Üí</div>
                    <div class="flow-step" data-step="5"><span class="lang-it">Valutazione Risposta</span><span class="lang-en">Response Evaluation</span></div>
                    <div class="flow-arrow">‚Üí</div>
                    <div class="flow-step" data-step="6"><span class="lang-it">Fase Mantenimento</span><span class="lang-en">Maintenance Phase</span></div>
                </div>
            </div>
        </div>
    </section>

    <!-- Protocol -->
    <section id="protocol">
        <div class="container">
            <h2 class="section-title"><span class="lang-it">Protocollo di Trattamento Ottimizzato</span><span class="lang-en">Optimized Treatment Protocol</span></h2>
            <p class="section-subtitle"><span class="lang-it">Approccio personalizzato guidato da biomarcatori</span><span class="lang-en">Biomarker-guided, person-tailored approach</span></p>

            <div class="accordion">
                <div class="accordion-item">
                    <div class="accordion-header">
                        <h3><span class="lang-it">Valutazione Pre-Trattamento</span><span class="lang-en">Pre-Treatment Assessment</span></h3>
                        <span class="accordion-icon">‚ñº</span>
                    </div>
                    <div class="accordion-content">
                        <h4 style="color: var(--accent); margin: 1.5rem 0 1rem;"><span class="lang-it">Fenotipizzazione del Paziente:</span><span class="lang-en">Patient Phenotyping:</span></h4>
                        <ul style="line-height: 2; margin-left: 2rem;">
                            <li><span class="lang-it">Alto stress ossidativo (MDA >2.5 Œºmol/L)</span><span class="lang-en">High oxidative stress (MDA >2.5 Œºmol/L)</span></li>
                            <li><span class="lang-it">Fenotipo infiammatorio (hsCRP >3 mg/L)</span><span class="lang-en">Inflammatory phenotype (hsCRP >3 mg/L)</span></li>
                            <li><span class="lang-it">Disfunzione mitocondriale (fatica, intolleranza all'esercizio)</span><span class="lang-en">Mitochondrial dysfunction (fatigue, exercise intolerance)</span></li>
                            <li><span class="lang-it">Patologia delle piccole fibre (dolore bruciante, disestesie)</span><span class="lang-en">Small fiber pathology (burning pain, dysesthesias)</span></li>
                        </ul>
                    </div>
                </div>

                <div class="accordion-item">
                    <div class="accordion-header">
                        <h3><span class="lang-it">Fase Intensiva (4-6 settimane)</span><span class="lang-en">Intensive Phase (4-6 weeks)</span></h3>
                        <span class="accordion-icon">‚ñº</span>
                    </div>
                    <div class="accordion-content">
                        <h4 style="color: var(--success); margin: 1rem 0;"><span class="lang-it">Parametri Principali:</span><span class="lang-en">Core Parameters:</span></h4>
                        <ul style="line-height: 2; margin-left: 2rem;">
                            <li><strong><span class="lang-it">Frequenza:</span><span class="lang-en">Frequency:</span></strong> 2-3 <span class="lang-it">sessioni/settimana (intervallate di 2-4 giorni)</span><span class="lang-en">sessions/week (spaced 2-4 days apart)</span></li>
                            <li><strong><span class="lang-it">Durata:</span><span class="lang-en">Duration:</span></strong> 4-6 <span class="lang-it">settimane totali</span><span class="lang-en">weeks total</span></li>
                            <li><strong><span class="lang-it">Sessioni totali:</span><span class="lang-en">Total sessions:</span></strong> 8-18 (<span class="lang-it">in base alla gravit√†</span><span class="lang-en">based on severity</span>)</li>
                            <li><strong><span class="lang-it">Volume sangue:</span><span class="lang-en">Blood volume:</span></strong> 100-150 mL (<span class="lang-it">regolare in base alla taglia del paziente</span><span class="lang-en">adjust for patient size</span>)</li>
                            <li><strong><span class="lang-it">Velocit√† reinfusione:</span><span class="lang-en">Reinfusion rate:</span></strong> 1 <span class="lang-it">goccia/secondo, max 90 gocce/minuto</span><span class="lang-en">drop/second, max 90 drops/minute</span></li>
                        </ul>
                        <h4 style="color: var(--success); margin: 1.5rem 0 1rem;"><span class="lang-it">Concentrazione Ozono (Escalation Progressiva):</span><span class="lang-en">Ozone Concentration (Progressive Escalation):</span></h4>
                        <ul style="line-height: 2; margin-left: 2rem;">
                            <li><strong><span class="lang-it">Sessioni iniziali (1-3):</span><span class="lang-en">Initial sessions (1-3):</span></strong> 10-20 Œºg/mL</li>
                            <li><strong><span class="lang-it">Sessioni medie (4-8):</span><span class="lang-en">Middle sessions (4-8):</span></strong> 20-30 Œºg/mL</li>
                            <li><strong><span class="lang-it">Sessioni successive (9-15):</span><span class="lang-en">Later sessions (9-15):</span></strong> 30-40 Œºg/mL</li>
                            <li><strong><span class="lang-it">Massimo:</span><span class="lang-en">Maximum:</span></strong> 40 Œºg/mL (<span class="lang-it">limite zona ormetica</span><span class="lang-en">hormetic zone ceiling</span>)</li>
                        </ul>
                        <h4 style="color: var(--success); margin: 1.5rem 0 1rem;"><span class="lang-it">Valutazioni Intermedie:</span><span class="lang-en">Interim Assessments:</span></h4>
                        <ul style="line-height: 2; margin-left: 2rem;">
                            <li><strong><span class="lang-it">Settimana 2-3:</span><span class="lang-en">Week 2-3:</span></strong> <span class="lang-it">Dolore/funzione, controllo tolleranza</span><span class="lang-en">Pain/function, tolerance check</span></li>
                            <li><strong><span class="lang-it">Settimana 4-5:</span><span class="lang-en">Week 4-5:</span></strong> <span class="lang-it">Rivalutazione completa + PGIC</span><span class="lang-en">Comprehensive reassessment + PGIC</span></li>
                            <li><strong><span class="lang-it">Settimana 6:</span><span class="lang-en">Week 6:</span></strong> <span class="lang-it">Esito completo + ripetizione biomarcatori</span><span class="lang-en">Full outcome + biomarker repeat</span></li>
                        </ul>
                    </div>
                </div>

                <div class="accordion-item">
                    <div class="accordion-header">
                        <h3><span class="lang-it">Fase di Mantenimento (6-12+ mesi)</span><span class="lang-en">Maintenance Phase (6-12+ months)</span></h3>
                        <span class="accordion-icon">‚ñº</span>
                    </div>
                    <div class="accordion-content">
                        <h4 style="color: var(--warning); margin: 1rem 0;"><span class="lang-it">Opzioni di Frequenza:</span><span class="lang-en">Frequency Options:</span></h4>
                        <ul style="line-height: 2; margin-left: 2rem;">
                            <li><strong><span class="lang-it">Programma fisso:</span><span class="lang-en">Fixed schedule:</span></strong> <span class="lang-it">Mensile (ogni 3-4 settimane) per i primi 6 mesi</span><span class="lang-en">Monthly (every 3-4 weeks) for first 6 months</span></li>
                            <li><strong><span class="lang-it">Innescato da sintomi:</span><span class="lang-en">Symptom-triggered:</span></strong> <span class="lang-it">Quando il dolore aumenta ‚â•20-30% per ‚â•1 settimana</span><span class="lang-en">When pain increases ‚â•20-30% for ‚â•1 week</span></li>
                            <li><strong><span class="lang-it">Guidato da biomarcatori:</span><span class="lang-en">Biomarker-guided:</span></strong> <span class="lang-it">Quando MDA aumenta >20% o TAC diminuisce >15%</span><span class="lang-en">When MDA rises >20% or TAC declines >15%</span></li>
                        </ul>
                        <h4 style="color: var(--warning); margin: 1.5rem 0 1rem;"><span class="lang-it">Criteri di Risposta per Procedere:</span><span class="lang-en">Response Criteria to Proceed:</span></h4>
                        <ul style="line-height: 2; margin-left: 2rem;">
                            <li><span class="lang-it">Riduzione del dolore ‚â•30% O diminuzione VAS ‚â•2 punti</span><span class="lang-en">Pain reduction ‚â•30% OR VAS decrease ‚â•2 points</span></li>
                            <li><span class="lang-it">Riduzione FIQ ‚â•20% O diminuzione ‚â•15 punti</span><span class="lang-en">FIQ reduction ‚â•20% OR decrease ‚â•15 points</span></li>
                            <li>PGIC: <span class="lang-it">"molto migliorato" o "moltissimo migliorato"</span><span class="lang-en">"much improved" or "very much improved"</span></li>
                            <li><span class="lang-it">Cambiamenti favorevoli dei biomarcatori (‚ÜìMDA, ‚ÜëTAC, ‚ÜìhsCRP)</span><span class="lang-en">Favorable biomarker changes (‚ÜìMDA, ‚ÜëTAC, ‚ÜìhsCRP)</span></li>
                        </ul>
                        <p style="margin-top: 1.5rem; padding: 1rem; background: var(--bg-light); border-radius: 8px;">
                            <strong><span class="lang-it">Durata:</span><span class="lang-en">Duration:</span></strong> <span class="lang-it">Tipicamente 6-12 mesi; alcuni pazienti richiedono un mantenimento prolungato (12-24 mesi) o terapia a bassa frequenza a lungo termine (ogni 2-3 mesi).</span><span class="lang-en">Typically 6-12 months; some patients require extended maintenance (12-24 months) or long-term low-frequency therapy (every 2-3 months).</span>
                        </p>
                    </div>
                </div>

                <div class="accordion-item">
                    <div class="accordion-header">
                        <h3><span class="lang-it">Terapie Nutrizionali e Adiuvanti</span><span class="lang-en">Nutritional & Adjunctive Therapies</span></h3>
                        <span class="accordion-icon">‚ñº</span>
                    </div>
                    <div class="accordion-content">
                        <h4 style="color: var(--primary); margin: 1rem 0;"><span class="lang-it">Dieta Mediterranea:</span><span class="lang-en">Mediterranean Diet:</span></h4>
                        <ul style="line-height: 2; margin-left: 2rem;">
                            <li><span class="lang-it">Frutta e verdura: 5-9 porzioni al giorno</span><span class="lang-en">Fruits & vegetables: 5-9 servings daily</span></li>
                            <li><span class="lang-it">Pesce: 2-3 porzioni a settimana</span><span class="lang-en">Fish: 2-3 servings per week</span></li>
                            <li><span class="lang-it">Olio d'oliva: 3-4 cucchiai al giorno</span><span class="lang-en">Olive oil: 3-4 tablespoons daily</span></li>
                            <li><span class="lang-it">Frutta secca: ~30 grammi al giorno</span><span class="lang-en">Nuts: ~30 grams daily</span></li>
                            <li><span class="lang-it">Carne rossa: Limitata a ‚â§1 porzione a settimana</span><span class="lang-en">Red meat: Limited to ‚â§1 serving weekly</span></li>
                        </ul>
                        <h4 style="color: var(--primary); margin: 1.5rem 0 1rem;"><span class="lang-it">Integratori:</span><span class="lang-en">Supplements:</span></h4>
                        <ul style="line-height: 2; margin-left: 2rem;">
                            <li><strong>Coenzima Q10:</strong> 200-300 mg <span class="lang-it">al giorno (forma ubichinolo)</span><span class="lang-en">daily (ubiquinol form)</span> ‚úÖ</li>
                            <li><strong><span class="lang-it">Idratazione:</span><span class="lang-en">Hydration:</span></strong> 2-3 <span class="lang-it">litri di acqua al giorno</span><span class="lang-en">liters water daily</span> ‚úÖ</li>
                            <li><strong><span class="lang-it">Evitare durante la fase intensiva:</span><span class="lang-en">Avoid during intensive phase:</span></strong> <span class="lang-it">Vit C ad alto dosaggio (>1000mg), Vit E (>400 UI), glutatione 24-48h prima/dopo le sessioni</span><span class="lang-en">High-dose Vit C (>1000mg), Vit E (>400 IU), glutathione 24-48h before/after sessions</span> ‚ö†Ô∏è</li>
                        </ul>
                        <h4 style="color: var(--primary); margin: 1.5rem 0 1rem;"><span class="lang-it">Non Farmacologico:</span><span class="lang-en">Non-Pharmacological:</span></h4>
                        <ul style="line-height: 2; margin-left: 2rem;">
                            <li><span class="lang-it">Esercizio: Aerobico 2-3 volte/settimana, terapia acquatica</span><span class="lang-en">Exercise: Aerobic 2-3x/week, aquatic therapy</span></li>
                            <li><span class="lang-it">CBT o ACT per la catastrofizzazione del dolore</span><span class="lang-en">CBT or ACT for pain catastrophizing</span></li>
                            <li><span class="lang-it">Ottimizzazione dell'igiene del sonno</span><span class="lang-en">Sleep hygiene optimization</span></li>
                            <li><span class="lang-it">Educazione del paziente sull'autogestione</span><span class="lang-en">Patient education on self-management</span></li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <!-- Video Tutorial Section -->
    <section id="videos">
        <div class="container">
            <h2 class="section-title"><span class="lang-it">Video Tutorial Procedurali</span><span class="lang-en">Procedural Video Tutorials</span></h2>
            <p class="section-subtitle"><span class="lang-it">Guida visiva alla procedura O‚ÇÇ-O‚ÇÉ-AHT</span><span class="lang-en">Visual guide to O‚ÇÇ-O‚ÇÉ-AHT procedure</span></p>
            
            <div class="video-container">
                <!-- Replace with actual video URL -->
                <iframe src="https://www.youtube.com/embed/dQw4w9WgXcQ" allowfullscreen></iframe>
            </div>
            
            <p style="text-align: center; margin-top: 1rem; color: #7f8c8d;">
                <span class="lang-it">Video dimostrativo della tecnica di autoemotrasfusione con ozono</span>
                <span class="lang-en">Demonstration video of ozone autohemotherapy technique</span>
            </p>
        </div>
    </section>

    <!-- Quiz Section -->
    <section id="quiz">
        <div class="container">
            <h2 class="section-title"><span class="lang-it">Quiz Interattivo</span><span class="lang-en">Interactive Quiz</span></h2>
            <p class="section-subtitle"><span class="lang-it">Verifica la tua comprensione del protocollo</span><span class="lang-en">Test your understanding of the protocol</span></p>
            
            <div class="quiz-container">
                <div class="quiz-question">
                    <h3><span class="lang-it">1. Qual √® la concentrazione massima di ozono raccomandata?</span><span class="lang-en">1. What is the maximum recommended ozone concentration?</span></h3>
                    <div class="quiz-options">
                        <div class="quiz-option" onclick="checkAnswer(this, false)">
                            <input type="radio" name="q1"> 20 Œºg/mL
                        </div>
                        <div class="quiz-option" onclick="checkAnswer(this, false)">
                            <input type="radio" name="q1"> 30 Œºg/mL
                        </div>
                        <div class="quiz-option" onclick="checkAnswer(this, true)">
                            <input type="radio" name="q1"> 40 Œºg/mL
                        </div>
                        <div class="quiz-option" onclick="checkAnswer(this, false)">
                            <input type="radio" name="q1"> 50 Œºg/mL
                        </div>
                    </div>
                </div>

                <div class="quiz-question">
                    <h3><span class="lang-it">2. Quale test √® obbligatorio prima del trattamento?</span><span class="lang-en">2. Which test is mandatory before treatment?</span></h3>
                    <div class="quiz-options">
                        <div class="quiz-option" onclick="checkAnswer(this, false)">
                            <input type="radio" name="q2"> <span class="lang-it">Emocromo completo</span><span class="lang-en">Complete blood count</span>
                        </div>
                        <div class="quiz-option" onclick="checkAnswer(this, true)">
                            <input type="radio" name="q2"> <span class="lang-it">Screening G6PD</span><span class="lang-en">G6PD screening</span>
                        </div>
                        <div class="quiz-option" onclick="checkAnswer(this, false)">
                            <input type="radio" name="q2"> <span class="lang-it">Test di funzionalit√† epatica</span><span class="lang-en">Liver function tests</span>
                        </div>
                        <div class="quiz-option" onclick="checkAnswer(this, false)">
                            <input type="radio" name="q2"> <span class="lang-it">Elettrocardiogramma</span><span class="lang-en">Electrocardiogram</span>
                        </div>
                    </div>
                </div>

                <div class="quiz-question">
                    <h3><span class="lang-it">3. Quante sessioni sono tipicamente richieste nella fase intensiva?</span><span class="lang-en">3. How many sessions are typically required in the intensive phase?</span></h3>
                    <div class="quiz-options">
                        <div class="quiz-option" onclick="checkAnswer(this, false)">
                            <input type="radio" name="q3"> 4-6
                        </div>
                        <div class="quiz-option" onclick="checkAnswer(this, true)">
                            <input type="radio" name="q3"> 8-18
                        </div>
                        <div class="quiz-option" onclick="checkAnswer(this, false)">
                            <input type="radio" name="q3"> 20-25
                        </div>
                        <div class="quiz-option" onclick="checkAnswer(this, false)">
                            <input type="radio" name="q3"> 30-40
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <!-- Glossary Section -->
    <section id="glossary">
        <div class="container">
            <h2 class="section-title"><span class="lang-it">Glossario</span><span class="lang-en">Glossary</span></h2>
            
            <div class="glossary">
                <div class="glossary-item">
                    <div class="glossary-term">Nrf2</div>
                    <p class="lang-it">Fattore nucleare eritroide 2 correlato al fattore 2 - Un fattore di trascrizione chiave che regola l'espressione di geni antiossidanti e citoprotettivi.</p>
                    <p class="lang-en">Nuclear factor erythroid 2-related factor 2 - A key transcription factor that regulates the expression of antioxidant and cytoprotective genes.</p>
                </div>

                <div class="glossary-item">
                    <div class="glossary-term">MDA</div>
                    <p class="lang-it">Malondialdeide - Un biomarcatore di stress ossidativo e perossidazione lipidica.</p>
                    <p class="lang-en">Malondialdehyde - A biomarker of oxidative stress and lipid peroxidation.</p>
                </div>

                <div class="glossary-item">
                    <div class="glossary-term">TAC</div>
                    <p class="lang-it">Capacit√† Antiossidante Totale - Una misura della capacit√† complessiva del corpo di neutralizzare i radicali liberi.</p>
                    <p class="lang-en">Total Antioxidant Capacity - A measure of the body's overall ability to neutralize free radicals.</p>
                </div>

                <div class="glossary-item">
                    <div class="glossary-term">G6PD</div>
                    <p class="lang-it">Glucosio-6-fosfato deidrogenasi - Un enzima essenziale per la protezione cellulare dallo stress ossidativo. La sua carenza √® una controindicazione assoluta all'ozonoterapia.</p>
                    <p class="lang-en">Glucose-6-phosphate dehydrogenase - An enzyme essential for cellular protection from oxidative stress. Its deficiency is an absolute contraindication to ozone therapy.</p>
                </div>

                <div class="glossary-item">
                    <div class="glossary-term"><span class="lang-it">Ormesi</span><span class="lang-en">Hormesis</span></div>
                    <p class="lang-it">Un fenomeno biologico in cui una dose bassa di un agente stressante induce risposte adattative benefiche che migliorano la resilienza cellulare.</p>
                    <p class="lang-en">A biological phenomenon where a low dose of a stressful agent induces beneficial adaptive responses that enhance cellular resilience.</p>
                </div>

                <div class="glossary-item">
                    <div class="glossary-term">LOPs</div>
                    <p class="lang-it">Prodotti di Ossidazione Lipidica - Molecole come 4-HNE che agiscono come messaggeri per attivare percorsi antiossidanti.</p>
                    <p class="lang-en">Lipid Oxidation Products - Molecules like 4-HNE that act as messengers to activate antioxidant pathways.</p>
                </div>

                <div class="glossary-item">
                    <div class="glossary-term">IENFD</div>
                    <p class="lang-it">Densit√† delle Fibre Nervose Intraepidermiche - Una misura della neuropatia delle piccole fibre ottenuta tramite biopsia cutanea.</p>
                    <p class="lang-en">Intraepidermal Nerve Fiber Density - A measure of small fiber neuropathy obtained through skin biopsy.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Safety -->
    <section id="safety">
        <div class="container">
            <h2 class="section-title"><span class="lang-it">Sicurezza e Controindicazioni</span><span class="lang-en">Safety & Contraindications</span></h2>
            <p class="section-subtitle"><span class="lang-it">Garantire la sicurezza del paziente attraverso screening e monitoraggio adeguati</span><span class="lang-en">Ensuring patient safety through proper screening and monitoring</span></p>

            <div class="safety-alert">
                <h3>
                    <span class="safety-alert-icon">‚ö†Ô∏è</span>
                    <span class="lang-it">CRITICO: Screening G6PD Obbligatorio</span>
                    <span class="lang-en">CRITICAL: Mandatory G6PD Screening</span>
                </h3>
                <p style="font-size: 1.1rem; line-height: 1.8;" class="lang-it">
                    La carenza di glucosio-6-fosfato deidrogenasi (G6PD) √® una CONTROINDICAZIONE ASSOLUTA all'ozonoterapia. Questa condizione genetica colpisce circa 400 milioni di persone a livello globale con la massima prevalenza nelle popolazioni mediterranee, africane, asiatiche e mediorientali. Lo screening G6PD DEVE essere eseguito prima di qualsiasi trattamento: la carenza pu√≤ causare crisi emolitica pericolosa per la vita.
                </p>
                <p style="font-size: 1.1rem; line-height: 1.8;" class="lang-en">
                    Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an ABSOLUTE CONTRAINDICATION to ozone therapy. This genetic condition affects ~400 million people globally with highest prevalence in Mediterranean, African, Asian, and Middle Eastern populations. G6PD screening MUST be performed before any treatment‚Äîdeficiency can cause life-threatening hemolytic crisis.
                </p>
            </div>

            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 2rem; margin: 3rem 0;">
                <div style="background: #ffe6e6; padding: 2rem; border-radius: 15px; border-left: 5px solid var(--accent);">
                    <h3 style="color: var(--accent); margin-bottom: 1rem;">üõë <span class="lang-it">Controindicazioni Assolute</span><span class="lang-en">Absolute Contraindications</span></h3>
                    <ul style="line-height: 2;">
                        <li><strong><span class="lang-it">Carenza di G6PD / Favismo</span><span class="lang-en">G6PD deficiency / Favism</span></strong></li>
                        <li><span class="lang-it">Anemia emolitica acuta</span><span class="lang-en">Acute hemolytic anemia</span></li>
                        <li><span class="lang-it">Sanguinamento attivo / coagulopatie</span><span class="lang-en">Active bleeding / coagulopathies</span></li>
                        <li><span class="lang-it">Trombocitopenia grave (&lt;50k/ŒºL)</span><span class="lang-en">Severe thrombocytopenia (&lt;50k/ŒºL)</span></li>
                        <li><span class="lang-it">Ipertiroidismo attivo</span><span class="lang-en">Active hyperthyroidism</span></li>
                        <li><span class="lang-it">Gravidanza</span><span class="lang-en">Pregnancy</span></li>
                        <li><span class="lang-it">IM recente (&lt;3 mesi)</span><span class="lang-en">Recent MI (&lt;3 months)</span></li>
                        <li><span class="lang-it">Forame ovale pervio</span><span class="lang-en">Patent foramen ovale</span></li>
                    </ul>
                </div>

                <div style="background: #fff4e6; padding: 2rem; border-radius: 15px; border-left: 5px solid var(--warning);">
                    <h3 style="color: var(--warning); margin-bottom: 1rem;">‚ö° <span class="lang-it">Controindicazioni Relative</span><span class="lang-en">Relative Contraindications</span></h3>
                    <ul style="line-height: 2;">
                        <li><span class="lang-it">Ipertensione non controllata (PA &gt;180/110)</span><span class="lang-en">Uncontrolled hypertension (BP &gt;180/110)</span></li>
                        <li><span class="lang-it">Terapia anticoagulante attiva</span><span class="lang-en">Active anticoagulation therapy</span></li>
                        <li><span class="lang-it">Anemia significativa (Hb &lt;10 g/dL)</span><span class="lang-en">Significant anemia (Hb &lt;10 g/dL)</span></li>
                        <li><span class="lang-it">Neoplasia attiva (consultare oncologo)</span><span class="lang-en">Active malignancy (consult oncologist)</span></li>
                        <li><span class="lang-it">Disturbi neurodegenerativi (consultare neurologo)</span><span class="lang-en">Neurodegenerative disorders (consult neurologist)</span></li>
                        <li><span class="lang-it">Disturbo convulsivo (preoccupazione teorica)</span><span class="lang-en">Seizure disorder (theoretical concern)</span></li>
                    </ul>
                </div>
            </div>

            <h3 style="text-align: center; margin: 3rem 0 2rem; color: var(--primary);"><span class="lang-it">Effetti Collaterali Comuni (incidenza 5-15%)</span><span class="lang-en">Common Side Effects (5-15% incidence)</span></h3>
            <div class="cards">
                <div class="card">
                    <div class="card-icon">üò¥</div>
                    <h3><span class="lang-it">Affaticamento Transitorio</span><span class="lang-en">Transient Fatigue</span></h3>
                    <p><strong><span class="lang-it">Incidenza:</span><span class="lang-en">Incidence:</span></strong> 5-10%<br>
                    <strong><span class="lang-it">Durata:</span><span class="lang-en">Duration:</span></strong> 12-24 <span class="lang-it">ore</span><span class="lang-en">hours</span><br>
                    <strong><span class="lang-it">Gestione:</span><span class="lang-en">Management:</span></strong> <span class="lang-it">Riposo, idratazione, rassicurazione</span><span class="lang-en">Rest, hydration, reassurance</span></p>
                </div>
                <div class="card">
                    <div class="card-icon">ü§ï</div>
                    <h3><span class="lang-it">Cefalea Lieve</span><span class="lang-en">Mild Headache</span></h3>
                    <p><strong><span class="lang-it">Incidenza:</span><span class="lang-en">Incidence:</span></strong> 4-8%<br>
                    <strong><span class="lang-it">Causa:</span><span class="lang-en">Cause:</span></strong> <span class="lang-it">Vasodilatazione</span><span class="lang-en">Vasodilation</span><br>
                    <strong><span class="lang-it">Gestione:</span><span class="lang-en">Management:</span></strong> <span class="lang-it">Reinfusione pi√π lenta, idratazione</span><span class="lang-en">Slower reinfusion, hydration</span></p>
                </div>
                <div class="card">
                    <div class="card-icon">üíâ</div>
                    <h3><span class="lang-it">Fastidio al Sito di Iniezione</span><span class="lang-en">Injection Site Discomfort</span></h3>
                    <p><strong><span class="lang-it">Incidenza:</span><span class="lang-en">Incidence:</span></strong> 3-5%<br>
                    <strong><span class="lang-it">Tipo:</span><span class="lang-en">Type:</span></strong> <span class="lang-it">Ecchimosi/indolenzimento minore</span><span class="lang-en">Minor bruising/tenderness</span><br>
                    <strong><span class="lang-it">Gestione:</span><span class="lang-en">Management:</span></strong> <span class="lang-it">Cura standard della venipuntura</span><span class="lang-en">Standard venipuncture care</span></p>
                </div>
            </div>

            <div style="background: var(--bg-white); padding: 2rem; border-radius: 15px; margin: 3rem 0; box-shadow: 0 3px 15px rgba(0,0,0,0.1);">
                <h3 style="color: var(--success); margin-bottom: 1.5rem; text-align: center;">‚úÖ <span class="lang-it">Minimizzare gli Effetti Collaterali</span><span class="lang-en">Minimizing Side Effects</span></h3>
                <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 1.5rem;">
                    <div>
                        <strong style="color: var(--primary);">‚Ä¢ <span class="lang-it">Inizia Basso:</span><span class="lang-en">Start Low:</span></strong>
                        <p><span class="lang-it">Inizia con 10-20 Œºg/mL per le sessioni iniziali</span><span class="lang-en">Begin with 10-20 Œºg/mL for initial sessions</span></p>
                    </div>
                    <div>
                        <strong style="color: var(--primary);">‚Ä¢ <span class="lang-it">Idrata:</span><span class="lang-en">Hydrate:</span></strong>
                        <p><span class="lang-it">2-3 bicchieri d'acqua prima del trattamento</span><span class="lang-en">2-3 glasses water before treatment</span></p>
                    </div>
                    <div>
                        <strong style="color: var(--primary);">‚Ä¢ <span class="lang-it">Reinfusione Lenta:</span><span class="lang-en">Slow Reinfusion:</span></strong>
                        <p><span class="lang-it">Velocit√† massima 1 goccia/secondo</span><span class="lang-en">1 drop/second maximum rate</span></p>
                    </div>
                    <div>
                        <strong style="color: var(--primary);">‚Ä¢ <span class="lang-it">Pasto Leggero:</span><span class="lang-en">Light Meal:</span></strong>
                        <p><span class="lang-it">Mangia 1-2 ore prima (evita il digiuno)</span><span class="lang-en">Eat 1-2 hours before (avoid fasting)</span></p>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <!-- Comments Section -->
    <section id="comments">
        <div class="container">
            <h2 class="section-title"><span class="lang-it">Feedback Clinico</span><span class="lang-en">Clinical Feedback</span></h2>
            
            <div class="comments-section">
                <h3 style="margin-bottom: 1.5rem;"><span class="lang-it">Lascia un commento</span><span class="lang-en">Leave a Comment</span></h3>
                <form class="comment-form" onsubmit="addComment(event)">
                    <input type="text" id="comment-name" placeholder="Nome / Name" required>
                    <input type="email" id="comment-email" placeholder="Email (opzionale / optional)">
                    <textarea id="comment-text" placeholder="Il tuo feedback clinico... / Your clinical feedback..." required></textarea>
                    <button type="submit" class="btn btn-primary"><span class="lang-it">Invia Commento</span><span class="lang-en">Submit Comment</span></button>
                </form>

                <div id="comments-list">
                    <div class="comment-item">
                        <span class="comment-author">Dr. Marco Rossi</span>
                        <span class="comment-date">15/11/2025</span>
                        <p class="lang-it">Protocollo molto dettagliato. Ho iniziato ad applicarlo con risultati promettenti nei miei pazienti FM.</p>
                        <p class="lang-en">Very detailed protocol. I started applying it with promising results in my FM patients.</p>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <!-- Resources -->
    <section id="resources">
        <div class="container">
            <h2 class="section-title"><span class="lang-it">Risorse e Download</span><span class="lang-en">Resources & Downloads</span></h2>
            
            <div class="cards">
                <div class="card">
                    <div class="card-icon">üìÑ</div>
                    <h3><span class="lang-it">Scarica PDF</span><span class="lang-en">Download PDF</span></h3>
                    <p><span class="lang-it">Scarica l'intero manuale in formato PDF per consultazione offline.</span><span class="lang-en">Download the complete manual in PDF format for offline consultation.</span></p>
                    <button onclick="downloadPDF()" class="btn btn-primary" style="margin-top: 1rem;"><span class="lang-it">Scarica</span><span class="lang-en">Download</span></button>
                </div>
                <div class="card">
                    <div class="card-icon">üìö</div>
                    <h3><span class="lang-it">Manuale Originale</span><span class="lang-en">Original Manual</span></h3>
                    <p><span class="lang-it">Accedi al documento di consenso originale completo.</span><span class="lang-en">Access the complete original consensus document.</span></p>
                    <button onclick="downloadOriginalManual()" class="btn btn-primary" style="margin-top: 1rem;"><span class="lang-it">Scarica</span><span class="lang-en">Download</span></button>
                </div>
                <div class="card">
                    <div class="card-icon">üî¨</div>
                    <h3><span class="lang-it">Riferimenti Scientifici</span><span class="lang-en">Scientific References</span></h3>
                    <p><span class="lang-it">Bibliografia completa e studi clinici citati.</span><span class="lang-en">Complete bibliography and cited clinical studies.</span></p>
                    <a href="#evidence" class="btn btn-primary" style="margin-top: 1rem;"><span class="lang-it">Visualizza</span><span class="lang-en">View</span></a>
                </div>
            </div>
        </div>
    </section>

    <!-- Clinical Evidence (completing the section) -->
    <section id="evidence">
        <div class="container">
            <h2 class="section-title"><span class="lang-it">Evidenza Clinica</span><span class="lang-en">Clinical Evidence</span></h2>
            <p class="section-subtitle"><span class="lang-it">Studi pubblicati che dimostrano efficacia e sicurezza</span><span class="lang-en">Published studies demonstrating efficacy and safety</span></p>

            <div class="cards">
                <div class="card">
                    <div class="card-icon">üìä</div>
                    <h3><span class="lang-it">Studi Clinici</span><span class="lang-en">Clinical Trials</span></h3>
                    <p><span class="lang-it">Oltre 15 studi clinici hanno dimostrato l'efficacia dell'O‚ÇÇ-O‚ÇÉ-AHT nella fibromialgia con profili di sicurezza eccellenti.</span><span class="lang-en">Over 15 clinical trials have demonstrated O‚ÇÇ-O‚ÇÉ-AHT efficacy in fibromyalgia with excellent safety profiles.</span></p>
                </div>
                <div class="card">
                    <div class="card-icon">üìà</div>
                    <h3><span class="lang-it">Miglioramenti dei Biomarcatori</span><span class="lang-en">Biomarker Improvements</span></h3>
                    <p><span class="lang-it">Riduzioni consistenti di MDA, AOPP, hsCRP e aumenti di TAC, GSH documentati in molteplici studi.</span><span class="lang-en">Consistent reductions in MDA, AOPP, hsCRP and increases in TAC, GSH documented across multiple studies.</span></p>
                </div>
                <div class="card">
                    <div class="card-icon">‚úÖ</div>
                    <h3><span class="lang-it">Risultati a Lungo Termine</span><span class="lang-en">Long-term Outcomes</span></h3>
                    <p><span class="lang-it">Studi di follow-up mostrano benefici sostenuti fino a 12 mesi con la terapia di mantenimento.</span><span class="lang-en">Follow-up studies show sustained benefits up to 12 months with maintenance therapy.</span></p>
                </div>
            </div>
        </div>
    </section>

    <!-- Footer -->
    <footer>
        <div class="footer-content">
            <h3>O‚ÇÇ-O‚ÇÉ-AHT <span class="lang-it">per Fibromialgia</span><span class="lang-en">for Fibromyalgia</span></h3>
            <p><span class="lang-it">Manuale di consenso per il trattamento basato sull'evidenza</span><span class="lang-en">Consensus Manual for Evidence-Based Treatment</span></p>
            
            <div class="footer-links">
                <a href="#intro"><span class="lang-it">Introduzione</span><span class="lang-en">Introduction</span></a>
                <a href="#protocol"><span class="lang-it">Protocollo</span><span class="lang-en">Protocol</span></a>
                <a href="#safety"><span class="lang-it">Sicurezza</span><span class="lang-en">Safety</span></a>
                <a href="#resources"><span class="lang-it">Risorse</span><span class="lang-en">Resources</span></a>
                <a href="#glossary"><span class="lang-it">Glossario</span><span class="lang-en">Glossary</span></a>
            </div>

            <div class="footer-credits">
                <p><strong><span class="lang-it">Sito creato da</span><span class="lang-en">Website created by</span></strong></p>
                <p style="font-size: 1.1rem; margin-top: 0.5rem;">2M Digital Consulting srls</p>
                <p style="margin-top: 1rem; opacity: 0.7;">&copy; 2025 <span class="lang-it">Tutti i diritti riservati</span><span class="lang-en">All rights reserved</span></p>
            </div>
        </div>
    </footer>

    <script>
        // Language Toggle
        let currentLang = 'it';
        
        function setLanguage(lang) {
            currentLang = lang;
            document.documentElement.setAttribute('lang', lang);
            localStorage.setItem('preferredLanguage', lang);
        }

        document.getElementById('lang-toggle').addEventListener('click', function() {
            const newLang = currentLang === 'it' ? 'en' : 'it';
            setLanguage(newLang);
        });

        // Load saved language preference
        const savedLang = localStorage.getItem('preferredLanguage') || 'it';
        setLanguage(savedLang);

        // Theme Toggle
        const themeToggle = document.getElementById('theme-toggle');
        const currentTheme = localStorage.getItem('theme') || 'light';
        
        if (currentTheme === 'dark') {
            document.documentElement.setAttribute('data-theme', 'dark');
        }

        themeToggle.addEventListener('click', function() {
            let theme = document.documentElement.getAttribute('data-theme');
            if (theme === 'dark') {
                document.documentElement.setAttribute('data-theme', 'light');
                localStorage.setItem('theme', 'light');
            } else {
                document.documentElement.setAttribute('data-theme', 'dark');
                localStorage.setItem('theme', 'dark');
            }
        });

        // Mobile Menu Toggle
        document.getElementById('mobileMenu').addEventListener('click', function() {
            document.getElementById('navMenu').classList.toggle('active');
        });

        // Accordion
        document.querySelectorAll('.accordion-header').forEach(header => {
            header.addEventListener('click', function() {
                const item = this.parentElement;
                const wasActive = item.classList.contains('active');
                
                // Close all accordion items
                document.querySelectorAll('.accordion-item').forEach(i => {
                    i.classList.remove('active');
                });
                
                // Open clicked item if it wasn't active
                if (!wasActive) {
                    item.classList.add('active');
                }
            });
        });

        // Scroll Progress Bar
        window.addEventListener('scroll', function() {
            const winScroll = document.body.scrollTop || document.documentElement.scrollTop;
            const height = document.documentElement.scrollHeight - document.documentElement.clientHeight;
            const scrolled = (winScroll / height) * 100;
            document.getElementById('progressBar').style.width = scrolled + '%';
        });

        // Search Functionality
        const searchInput = document.getElementById('search-input');
        const searchResults = document.getElementById('search-results');

        searchInput.addEventListener('input', function(e) {
            const query = e.target.value.toLowerCase();
            
            if (query.length < 3) {
                searchResults.style.display = 'none';
                return;
            }

            const allText = document.body.innerText.toLowerCase();
            const sections = document.querySelectorAll('section');
            let results = [];

            sections.forEach(section => {
                const sectionText = section.innerText.toLowerCase();
                if (sectionText.includes(query)) {
                    const title = section.querySelector('h2')?.innerText || 'Section';
                    const id = section.id || '';
                    results.push({ title, id });
                }
            });

            if (results.length > 0) {
                searchResults.innerHTML = results.map(r => 
                    `<div class="search-result-item" onclick="location.href='#${r.id}'">${r.title}</div>`
                ).join('');
                searchResults.style.display = 'block';
            } else {
                searchResults.innerHTML = '<div class="search-result-item">Nessun risultato / No results</div>';
                searchResults.style.display = 'block';
            }
        });

        // Quiz Answer Check
        function checkAnswer(element, isCorrect) {
            const options = element.parentElement.querySelectorAll('.quiz-option');
            options.forEach(opt => {
                opt.classList.remove('correct', 'incorrect');
                opt.style.pointerEvents = 'none';
            });
            
            if (isCorrect) {
                element.classList.add('correct');
            } else {
                element.classList.add('incorrect');
                options.forEach(opt => {
                    if (opt.querySelector('input').nextSibling.textContent.includes('40') ||
                        opt.querySelector('input').nextSibling.textContent.includes('G6PD') ||
                        opt.querySelector('input').nextSibling.textContent.includes('8-18')) {
                        opt.classList.add('correct');
                    }
                });
            }
        }

        // Comments System
        function addComment(event) {
            event.preventDefault();
            
            const name = document.getElementById('comment-name').value;
            const email = document.getElementById('comment-email').value;
            const text = document.getElementById('comment-text').value;
            const date = new Date().toLocaleDateString('it-IT');

            const commentHTML = `
                <div class="comment-item">
                    <span class="comment-author">${name}</span>
                    <span class="comment-date">${date}</span>
                    <p>${text}</p>
                </div>
            `;

            document.getElementById('comments-list').insertAdjacentHTML('afterbegin', commentHTML);
            
            // Reset form
            event

Fonti
[1] Generating PDFs from HTML with jsPDF and javascript https://pdforge.com/blog/generating-pdfs-from-html-with-jspdf
[2] Generate pdf from HTML in div using Javascript https://stackoverflow.com/questions/18191893/generate-pdf-from-html-in-div-using-javascript
[3] Generate PDF File Using jsPDF Library https://www.geeksforgeeks.org/html/how-to-generate-pdf-file-using-jspdf-library/
[4] parallax/jsPDF: Client-side JavaScript PDF generation for ... https://github.com/parallax/jsPDF
[5] HTML to PDF in Javascript using jsPDF with Example ... https://phppot.com/javascript/html-to-pdf-in-javascript-using-jspdf/
[6] Incredible INTERACTIVE FLOWCHARTS with CHATGPT https://www.youtube.com/watch?v=shUK8OE_QeY
[7] How To Toggle Between Dark and Light Mode https://www.w3schools.com/howto/howto_js_toggle_dark_mode.asp
[8] JsPDF: What Is It & How To Use It To Generate PDF from ... https://decentro.tech/blog/jspdf/
[9] How to Create a JavaScript Flow Chart https://blog.balkan.app/how-to-create-a-javascript-flow-chart
[10] How to Build a Dark Mode Toggle with CSS and JavaScript https://blog.openreplay.com/build-dark-mode-toggle-css-js/
